Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2024-12-15 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物关于聘请H股发行及上市审计机构的公告
Board/Management Information Classification · 95% confidence The document is an announcement by the company about the intention to appoint Ernst & Young Hong Kong as the audit firm for its H-share issuance and listing. It details the qualifications and integrity of the proposed auditor, the approval process by the audit committee, board of directors, and supervisory board, and states that the appointment is subject to shareholder approval. The document does not contain any financial statements, audit reports, or detailed financial data. It is a formal announcement regarding a corporate governance and audit appointment matter, not the audit report itself or an annual report. Therefore, it fits best under Board/Management Information (MANG) as it relates to appointment of an audit firm, which is a management/board-level decision announcement.
2024-12-15 Chinese
迈威生物关于制定、修订H股发行后适用的《公司章程》及公司部分治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding the formulation and revision of the company's Articles of Association and certain governance rules following the issuance of H shares and listing on the Hong Kong Stock Exchange. It includes extensive legal and regulatory references, detailed amendments to the company's charter, shareholder rights, share issuance, and governance procedures. The content focuses on corporate governance and regulatory compliance related to share issuance and listing rules, rather than financial results, audit opinions, or meeting materials. It is not a full annual or interim report, nor a simple announcement of a report. The document is a governance-related announcement detailing changes to the company's internal rules and governance practices, which fits the category of Governance Information (CGR).
2024-12-15 Chinese
《迈威（上海）生物科技股份有限公司股东提名人选参选董事的程序》（草案）
Governance Information Classification · 95% confidence The document is titled as a procedural draft for shareholder nomination of director candidates, referencing relevant laws and listing rules, specifically the Hong Kong Stock Exchange Listing Rules. It outlines the nomination process, disclosure requirements, and timing related to shareholder meetings and director elections. There is no financial data, earnings information, or report publication mentioned. The content focuses on governance procedures and compliance with listing rules regarding board nominations. This fits the category of Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2024-12-15 Chinese
迈威生物关于制定公司部分治理制度的公告
Governance Information Classification · 95% confidence The document is an announcement from the company's board regarding the adoption of new internal governance policies and management systems. It references relevant laws and regulations and states that the new governance systems have been approved by the board and will take effect immediately without requiring shareholder approval. The document does not contain financial data, audit information, or detailed financial reports. It focuses on governance practices and internal management rules. Therefore, it fits the category of Governance Information (CGR). The document length is short and it is not merely announcing the publication of a report but is itself the announcement of governance policy adoption.
2024-12-15 Chinese
海通证券股份有限公司关于迈威（上海）生物科技股份有限公司部分募投项目增加实施主体并新设立募集资金专户事项的核查意见
Capital/Financing Update Classification · 95% confidence The document is from Haitong Securities acting as the sponsor for Maiwei (Shanghai) Biotechnology Co., Ltd. It discusses the verification opinion on the addition of implementation entities for some fundraising projects and the establishment of special fundraising accounts. It references regulatory guidelines related to fundraising management and usage, details the fundraising amounts, project investment plans, and approvals by the board and supervisory committee. The document is a formal verification opinion by the sponsor on fundraising project changes and related compliance, not a full financial report or earnings release. It is a regulatory compliance and verification statement related to capital raising and project fund management. The document length is about 2960 characters, relatively short and focused on a specific fundraising compliance matter. This fits best under Capital/Financing Update (CAP) as it concerns updates on fundraising activities and capital structure changes, rather than a full annual or interim report, audit report, or other categories.
2024-12-15 Chinese
《迈威（上海）生物科技股份有限公司股东会议事规则》（草案）
Governance Information Classification · 95% confidence The document is titled as "股东会议事规则(草案)" which translates to "Shareholders Meeting Rules (Draft)". It details the rules and procedures for convening and conducting shareholders' meetings, including voting rights, proposal submissions, meeting conduct, and legal compliance. It references relevant laws and listing rules applicable after the issuance and listing of H shares. The content is a governance document outlining internal rules and procedures for shareholder meetings rather than an announcement, report, or financial statement. It does not contain financial data, audit information, or meeting results. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-12-15 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.